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Systolic Hypertension,
Preeclampsia-Related
Mortality, and Stroke In
California
We read with interest the provocative
article by Judy et al in the June 2019
issue1 reporting a series of strokes re-
sulting from accelerated systolic
hypertension in women with pre-
eclampsia. Preceding stroke, all pa-
tients presented with blood pressure
greater than 160 mm Hg and classic
symptoms such as headache, visual
changes, abdominal pain, and nausea.
The authors rightly deplore that,
“Despite the near-universal occur-
rence of concerning signs and symp-
toms, few women in our series
received antihypertensive therapy
before the occurrence of stroke.” We
would like to point out that, with re-
gard to stroke prevention or cerebro-
protection, not all antihypertensive
drug classes are created equal. Given
the extremely limited armamentarium
of available antihypertensives in preg-
nancy, a careful therapeutic selection
is therefore exceedingly important.
Time and again it has been demon-
strated the beta blockers are suboptimal
with regard to stroke prevention. This
inefficacy may be related to their pseudo-
antihypertensive effect: blood pressure
seems to fall when measured peripherally
(upper arm) but remains elevated cen-
trally (aorta and cerebral circulation).2–4
Whether beta blockers, because of their
pseudo-antihypertensive effect, confer
any benefit at all or just provide to the
patient and physician a sense of false
security is currently hotly debated.
In contrast, long-acting calcium chan-
nel blockers (similar to chlorthalidone and
indapamide) are agents of choice for
stroke prevention, even more efficacious
than (pregnancy-contraindicated) blockers
of the renin angiotensin cascade.4–6
Although there are some data for the cal-
cium channel blockers amlodipine and dil-
tiazem, the data in pregnancy are best for
nifedipine, which is also emphasized by
most guidelines. Of note, hydralazine is
no longer considered a drug of choice
because its use is associated with more
perinatal adverse effects than other drugs.7
As Judy et al1 point out, the pathogen-
esis of stroke is multifactorial in pre-
eclampsia. Whether therapeutic insight
gathered in hypertensive cardiovascular
disease outside pregnancy can be extrap-
olated to patients with preeclampsia re-
mains unknown. Nevertheless, because
stroke remains the most devastating
maternal complication of preeclampsia,
it stands to reason to primarily prevent
it with the most efficacious cerebropro-
tective drug. Clearly, to achieve this goal,
long-acting calcium channel blockers are
far superior to beta blockers.
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In Reply:
We thank Dr. Messerli et al for their
thought-provoking commentary, which
asserts that long-acting calcium channel
blockers are superior to beta blockers for
the prevention of stroke in patients with
preeclampsia. We are not aware of any
randomized controlled trials in pregnant
women examining this specific issue, and
we urge caution in making significant
changes to practice based on observa-
tions in different patient populations.
The studies referenced by Messerli
et al examine nonpregnant populations
that are significantly older, with chronic
hypertension and other medical comor-
bidities.1 Though it is convenient to
extrapolate from the literature on non-
pregnant women, this must be resisted.
There are significant physiologic changes
in pregnancy, including peripheral vaso-
dilation and increases in blood volume
and cardiac output. Pharmacokinetic dif-
ferences are well documented. Long-
standing hypertension and medical co-
morbidities may affect vascular response
differently than acute preeclampsia, and
preeclampsia itself is known to alter phys-
iology.2 It cannot be assumed that find-
ings in a nonpregnant population will be
replicated in pregnant women.
Furthermore, stroke is not the only
devastating sequelae of preeclampsia-
associated severe hypertension,2,3 and
the choice of antihypertensive must
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